title: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer.
abstract: BACKGROUND
  Human complement factor H-related protein (hCFHrp) is produced by several bladder cancer cell lines and may be useful as a cancer marker. The aim of this study was to compare urinary hCFHrp and cytology for the detection of bladder cancer found by cystoscopy in patients with suggestive signs, symptoms, or preliminary test results.
  
  
  METHODS
  The BTA TRAK assay, a quantitative enzyme immunoassay for the bladder tumor-associated antigen in urine, was compared with exfoliative cytology in 220 patients (155 men, 65 women; mean age, 64.2 years) presenting with signs, symptoms, or preliminary diagnostic results suggestive of this disease. Cystoscopy was the standard of detection.
  
  
  RESULTS
  In the 100 patients found to have bladder cancer, the overall sensitivities of the BTA TRAK assay (at a previously determined decision threshold of 14 kilounits/L) and cytology were 66% (66 of 100) and 33% (33 of 100), respectively (P <0.001). The BTA TRAK assay proved to be statistically more sensitive than cytology for tumor grades I and II and for stage Ta and T1 tumors. In contrast, the overall specificity of the BTA TRAK assay in the 120 patients without cystoscopically confirmed bladder cancer was 69% (83 of 120) and that of cytology was 99% (119 of 120; P <0.001). The specificity of the BTA TRAK assay was higher in patients without benign or malignant genitourinary disease other than bladder cancer (76%; n = 89) than in patients with these conditions. When the BTA TRAK assay and cytology were used together such that a positive result in either test was scored as positive and the results compared with those of the BTA TRAK assay alone, increases in overall sensitivity and equivalent specificity were observed.
  
  
  CONCLUSIONS
  Because of its relatively high sensitivity, the BTA TRAK assay could complement cytology as an adjunct to cystoscopy in the diagnosis and follow-up of most patients with bladder cancer.
authors: Laboratory Medicine, Krankenhaus Nordwest, Steinbacher Hohl 2, D-60489 Frankfurt, Germany. th-books@t-online.de
authors: L
authors: L
authors: Thomas
authors: H
authors: H
authors: Leyh
authors: M
authors: M
authors: Marberger
authors: E
authors: E
authors: Bombardieri
authors: P
authors: P
authors: Bassi
authors: F
authors: F
authors: Pagano
authors: V
authors: V
authors: Pansadoro
authors: C N
authors: CN
authors: Sternberg
authors: L
authors: L
authors: Boccon-Gibod
authors: V
authors: V
authors: Ravery
authors: D
authors: D
authors: Le Guludec
authors: A
authors: A
authors: Meulemans
authors: P
authors: P
authors: Conort
authors: L
authors: L
authors: Ishak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D017242:Complement Factor H / Q000652:urine*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000652:urine; D014556:Urine / Q000166:cytology
chemical_list: D014408:Biomarkers, Tumor; C493495:CFH protein, human; D011933:Reagent Kits, Diagnostic; D017242:Complement Factor H